SCHEMBL16232134

SCHEMBL16232134

Cc1ccc([C@H](N)C2CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.47
OPRD1 P41143 2/20 0.47
OPRK1 P41145 2/20 0.47
OPRL1 P41146 2/20 0.47
CHRNA7 P36544 1/20 0.38
ACHE P22303 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
MAOB P27338 5/20 0.33
MAOA P21397 4/20 0.33
METAP2 P50579 1/20 0.33
ALOX5 P09917 1/20 0.33
RPS6KB1 P23443 1/20 0.33
CA7 P43166 1/20 0.32
IDO1 P14902 1/20 0.32
AKT2 P31751 1/20 0.32
GSK3B P49841 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16232135 1.00 OPRM1 (0.47) OPRM1OPRD1OPRK1OPRL1CHRNA7
SCHEMBL16232133 1.00 OPRM1 (0.47) OPRM1OPRD1OPRK1OPRL1CHRNA7
SCHEMBL22868078 0.90 OPRM1 (0.44) OPRM1OPRD1OPRK1OPRL1MEN1
SCHEMBL3972540 0.79 MEN1 (0.38) OPRM1OPRD1OPRK1OPRL1ACHE
SCHEMBL12526093 0.77 HRH1 (0.47) OPRM1OPRD1OPRK1OPRL1CHRNA7
SCHEMBL1821736 0.77 ESR1 (0.41) OPRM1TDP1MEN1KMT2AIDO1
SCHEMBL2675532 0.77 RPS6KB1 (0.48) OPRM1OPRD1OPRK1OPRL1RPS6KB1
SCHEMBL1239995 0.77 RPS6KB1 (0.48) OPRM1OPRD1OPRK1OPRL1RPS6KB1
SCHEMBL3721733 0.77 OPRM1 (0.41) OPRM1OPRD1OPRK1OPRL1MAOB
SCHEMBL13885596 0.77 ACACB (0.37) OPRM1OPRD1OPRK1OPRL1RPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2023-10-10 US disclosed
US-9914702-B2 Amine derivatives as potassium channel blockers BIONOMICS LIMITED (AU) 2018-03-13 US disclosed
US-20170088519-A1 AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS BIONOMICS, LTD (AU) 2017-03-30 US disclosed
US-9493451-B2 Amine derivatives as potassium channel blockers BIONOMICS LIMITED (AU) 2016-11-15 US disclosed
US-20150299184-A1 Amine Derivatives as Potassium Channel Blockers BIONOMICS LIMITED (AU) 2015-10-22 US disclosed
US-20140336198-A1 Amine Derivatives as Potassium Channel Blockers MERCK PATENT GMBH (DE) 2014-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170088519-A1 AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS KCNA3, KCNH3, KCNK3 OPRM1 2319/4885OPRD1 1758/4885OPRK1 700/4885
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 OPRM1 4384/4885OPRD1 4380/4885OPRK1 4275/4885
US-20140336198-A1 Amine Derivatives as Potassium Channel Blockers KCNA3, KCNH3, KCNK3 OPRM1 2319/4885OPRD1 1758/4885OPRK1 700/4885
US-20150299184-A1 Amine Derivatives as Potassium Channel Blockers KCNA3, KCNH3, KCNK3 OPRM1 2319/4885OPRD1 1758/4885OPRK1 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.